Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 54,938 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Completed Phase 1 Interventional

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

NCT03113695
View directory record Official record
Conditions
Richter's Syndrome, CLL
Interventions
Obinutuzumab, lenalidomide, HDMP
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 2 Interventional

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

NCT00005081
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Nov 4, 2026, 10:42 AM EST
Terminated Phase 1 Interventional

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Nov 4, 2026, 10:42 AM EST
Terminated Phase 2 Interventional

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319
View directory record Official record
Conditions
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Long Beach, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Nov 4, 2026, 10:42 AM EST
Terminated Phase 3 Interventional

Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

NCT03016130
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Diet
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Nov 4, 2026, 10:42 AM EST
Completed Not applicable Interventional

Preoperative Massage in Breast Surgery Patients

NCT01667328
View directory record Official record
Conditions
Anxiety, Presurgical Anxiety, Breast Cancer
Interventions
Massage therapy, Standard of care
Procedure
Lead sponsor
Vassar Brothers Medical Center
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Poughkeepsie, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 1Phase 2 Interventional

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

NCT01576328
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mesenchymal Precursor Cells (MPCs)
Drug
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Garden Grove, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Nov 4, 2026, 10:42 AM EST
Terminated Phase 2 Interventional Results available

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Interventions
Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Months to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Nov 4, 2026, 10:42 AM EST
Recruiting Not applicable Interventional

A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients

NCT07322367
View directory record Official record
Conditions
Lung Cancer
Interventions
Portal Message with Reminder Text Messages, Text Message with Reminder Text Messages, Portal message only, Usual Care
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 77 Years
Enrollment
27,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Nov 4, 2026, 10:42 AM EST
Not yet recruiting Not applicable Interventional

The Impact of Meditation on Anxiety and Post-Operative Pain in Pediatric Patients Undergoing Urological Surgery

NCT06858267
View directory record Official record
Conditions
Pediatric Kidney Disease
Interventions
PeSSKi questionnaire survey, Meditation Video
Behavioral
Lead sponsor
Augusta University
Other
Eligibility
6 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Nov 4, 2026, 10:42 AM EST
Active, not recruiting Not applicable Interventional

Testing a Brief Reassurance Message Before a Musculoskeletal Clinic Visit

NCT07330492
View directory record Official record
Conditions
Any Non-traumatic Musculoskeletal Condition
Interventions
Nudge intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NCT00878436
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Panobinostat, Bicalutamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 1 Interventional

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

NCT01527136
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
entolimod, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Nov 4, 2026, 10:42 AM EST
Terminated Not applicable Interventional

Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study

NCT02800044
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Wearing a non-invasive glucose sensor
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 2 Interventional Results available

Short Course Daratumumab in Patients With Multiple Myeloma

NCT03490344
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 1 Interventional

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

NCT02697344
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study, R-(-)-Gossypol Acetic Acid
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Nov 4, 2026, 10:42 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

NCT05630209
View directory record Official record
Conditions
Brain Tumor
Interventions
Exablate, Doxorubicin
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 1 Interventional

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

NCT01264432
View directory record Official record
Conditions
Adult Solid Neoplasm, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy, Veliparib
Other · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 1 Interventional Results available

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

NCT00424632
View directory record Official record
Conditions
Solid Tumors
Interventions
PF-03814735
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Nov 4, 2026, 10:42 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies

NCT04020198
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Rapid Eye Movement Sleep Behavior Disorder, Normal Pressure Hydrocephalus
Interventions
Biomarker assay
Other
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

NCT03338998
View directory record Official record
Conditions
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Interventions
BAF312 solution, Matching Placebo for BAF312 solution, BAF312 tablet, Matching Placebo for BAF312 tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Nov 4, 2026, 10:42 AM EST
Completed Not applicable Interventional Results available

Standardized Patient-Centered Medication Review in Home Hospice

NCT03972163
View directory record Official record
Conditions
Hospices, Poly Pharmacy, Deprescriptions, Caregivers, Palliative Care, Prescription Drug Overuse, Interdisciplinary Communication
Interventions
NIA Medication Management - Active Comparator, STOPPFrail (Screening Tool of Older Persons Prescriptions), "Discontinuing Medication Appropriately" and "Understanding the Art of Communication about Deprescribing", "Key Approaches to Support Informal Family Caregivers in Managing Medications"
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
65 Years to 110 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 4, 2026, 10:42 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients

NCT00778063
View directory record Official record
Conditions
Otitis Media
Interventions
dexmedetomidine, saline
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
1 Year to 5 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Nov 4, 2026, 10:42 AM EST
Completed Phase 4 Interventional

A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

NCT00293163
View directory record Official record
Conditions
Facial Wrinkles
Interventions
Hylaform, Hylaform Plus (hylan B gel)
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
3
States / cities
Los Angeles, California • Warren, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Nov 4, 2026, 10:42 AM EST